Kawa Capital Management’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Kawa Capital Management’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-27,000	Closed	-$264K	–	13
2022 Q2	$264K	Hold	27,000	–	–	1.23%	23
2022 Q1	$263K	Hold	27,000	–	–	0.44%	43
2021 Q4	$262K	Buy	+27,000	New	+$263K	0.25%	60

Other funds holding EBAC

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Kawa Capital Management's EBAC Position: Q3 2022 in Review

Kawa Capital Management sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q3 2022, closing a stake of 27,000 shares — an estimated $264K sold.

Kawa Capital Management first reported a position in EBAC in Q4 2021 and held it in 3 quarters. The position peaked at $264K in Q2 2022. 50 funds tracked by Wall St. Rank hold EBAC as of Q3 2022.

Kawa Capital Management reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Kawa Capital Management sold 27,000 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q3 2022, an estimated $264K.
Kawa Capital Management first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q4 2021 and held it in 3 quarters.
Kawa Capital Management's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $264K in Q2 2022.
50 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q3 2022.

Based on Kawa Capital Management's 13F filing for Q3 2022.